Events & Resources

Learning Center
Read through guides, explore resource hubs, and sample our coverage.
Learn More
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More
Podcasts
Listen to our podcast, Behind the Numbers for the latest news and insights.
Learn More

About

Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More
Our Clients
Key decision-makers share why they find EMARKETER so critical.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us

Marty Makary’s FDA commissioner appointment and planned workforce cuts could affect drug approvals, pricing in pharma

The news: Dr. Marty Makary, a Johns Hopkins surgeon, was confirmed by the Senate this week as FDA commissioner. Makary will work underneath HHS Secretary Robert F. Kennedy Jr. and will lead an agency responsible for drugs, vaccines, and medical devices in the US.

Catch up quick: Makary’s medical background and less polarizing stance on issues like vaccines and proven science made his testimony before the Senate Health, Education, Labor and Pensions Committee less contentious than the HHS Secretary’s Senate hearings.

Yes, but: Makary appears aligned with Kennedy in a few key areas that could affect pharma companies—namely, cuts to the FDA workforce, prescription drug prices, and questioning vaccine effectiveness.

You've read 0 of 2 free articles this month.

Create an account for uninterrupted access to select articles.
Create a Free Account